Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb
Figure 1. Elisa plates were pre-coated with IgG-CL2A (0.2μg/per well). Serial diluted anti-CL2A monoclonal antibody solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CL2A monoclonal antibody binding with IgG-CL2A is 12.57ng/ml.
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Isotype : | Rabbit IgG |
| Purification : | Purified from cell culture supernatant by affinity chromatography |
| Content : | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Storage condition : | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
Description :Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb
CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
ELISA 1:5000-10000
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
